Vertex Pharmaceuticals
About
Vertex Pharmaceuticals dominates the cystic fibrosis treatment market with its Trikafta franchise, which generates billions in annual revenue and treats the underlying cause of the disease rather than just symptoms. The company is expanding into pain management, gene editing, kidney disease, and other serious conditions, building a diversified pipeline beyond its CF stronghold. It appeals to growth and healthcare investors seeking a profitable, cash-rich biotech with a proven commercial track record and multiple pipeline catalysts ahead.
Growth Stocks
Vertex combines the rare attributes of a profitable, cash-generative pharmaceutical company with a robust growth pipeline, offering investors both current earnings power and multiple catalysts for future revenue expansion.
Healthcare Stocks
Vertex is a leading healthcare innovator expanding beyond cystic fibrosis into pain, gene editing, and kidney disease, with a pipeline of potentially transformative therapies that could address large unmet medical needs.
Pharmaceutical Stocks
Vertex is the dominant pharmaceutical company in cystic fibrosis treatment, with its Trikafta franchise representing the standard of care and generating billions in highly profitable revenue with limited direct competition.
Key Financials VRTX
Price
$491.47
Change (1D)
+5.69%
Change (30D)
+8.41%
Change (60D)
+13.24%
Change (90D)
+21.98%
Change (180D)
+10.42%
Change (1Y)
+8.44%
Change (5Y)
+129.85%
P/E Ratio
35.03
EPS (TTM)
$14.03
52-Week Range
$362.50 — $519.68
50-Day MA
$460.32
Volume
2.92M
Data updated Feb 15 · Source: Twelve Data
